Xenon Pharmaceuticals Inc. - Product Pipeline Review - H2 2011
Global Markets Direct
November 28, 2011 45 Pages - SKU: GMD6692201
|
|
Xenon Pharmaceuticals Inc. - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Xenon Pharmaceuticals Inc. - Product Pipeline Review - H2 2011” provides data on the Xenon Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xenon Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Xenon Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope - Xenon Pharmaceuticals Inc. - Brief Xenon Pharmaceuticals Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Xenon Pharmaceuticals Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Xenon Pharmaceuticals Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Xenon Pharmaceuticals Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy - Evaluate Xenon Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Xenon Pharmaceuticals Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Xenon Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Xenon Pharmaceuticals Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Xenon Pharmaceuticals Inc. and identify potential opportunities in those areas.
|
- Xenon Pharmaceuticals Inc. Snapshot
- Xenon Pharmaceuticals Inc. Overview
- Key Information
- Key Facts
- Xenon Pharmaceuticals Inc. - Research and Development Overview
- Key Therapeutic Areas
- Xenon Pharmaceuticals Inc. - Pipeline Review
- Pipeline Products by Stage of Development
- Pipeline Products - Monotherapy
- Xenon Pharmaceuticals Inc. - Pipeline Products Glance
- Xenon Pharmaceuticals Inc. Clinical Stage Pipeline Products
- Phase II Products/Combination Treatment Modalities
- Phase I Products/Combination Treatment Modalities
- Xenon Pharmaceuticals Inc.-Early Stage Pipeline Products
- Pre-Clinical Products/Combination Treatment Modalities
- Discovery Products/Combination Treatment Modalities
- Xenon Pharmaceuticals Inc. - Drug Profiles
- Cardiovascular Program
- Product Description
- Mechanism of Action
- R&D Progress
- Drug For Anemia Of Inflammation
- Product Description
- Mechanism of Action
- R&D Progress
- Iron Overload Program
- Product Description
- Mechanism of Action
- R&D Progress
- Oral XEN402
- Product Description
- Mechanism of Action
- R&D Progress
- Stearoyl-CoA Desaturase-1 Drug Development Program
- Product Description
- Mechanism of Action
- R&D Progress
- Topical XEN402
- Product Description
- Mechanism of Action
- R&D Progress
- XEN403
- Product Description
- Mechanism of Action
- R&D Progress
- XPF-001
- Product Description
- Mechanism of Action
- R&D Progress
- XPF-002
- Product Description
- Mechanism of Action
- R&D Progress
- Xenon Pharmaceuticals Inc. - Pipeline Analysis
- Xenon Pharmaceuticals Inc. - Pipeline Products by Therapeutic Class
- Xenon Pharmaceuticals Inc. - Pipeline Products By Target
- Xenon Pharmaceuticals Inc. - Pipeline Products by Route of Administration
- Xenon Pharmaceuticals Inc. - Pipeline Products by Molecule Type
- Xenon Pharmaceuticals Inc. - Recent Pipeline Updates
- Xenon Pharmaceuticals Inc. - Dormant Projects
- Xenon Pharmaceuticals Inc. - Locations And Subsidiaries
- Head Office
- Recent Developments
- Sep 20, 2004: Xenon And Novartis Sign Drug Development Deal For Obesity And Metabolic Disorders
- Aug 17, 2010: Xenon Initiates Phase II Clinical Trial Of XEN 402 In Post Herpetic Neuralgia Patients
- Dec 07, 2006: Xenon Enters Into Anemia Collaboration With Roche
- Oct 03, 2006: Xenon And Takeda Announce Agreement To Develop And Commercialize XEN401 For Pain In Japan And Certain Asian Countries
- May 02, 2011: Xenon’s XEN402 Ointment Significantly Relieves Pain In Patients With Post Herpetic Neuralgia
- Financial Deals Landscape
- Xenon Pharmaceuticals Inc., Deals Summary
- Xenon Pharmaceuticals Inc., Pharmaceuticals & Healthcare, Deal Details
- Venture Financing
- Xenon Pharmaceuticals Secures $31 Million In Financing
- Partnerships
- Isis Pharmaceuticals Enters Into Collaboration With Xenon Pharmaceuticals
- Xenon Pharmaceuticals Enters Into Collaboration Agreement With DDI
- Xenon Enters Into Research Agreement With Roche
- Takeda Pharmaceutical Enters Into An Agreement With Xenon
- Licensing Agreements
- Xenon Pharmaceuticals Enters Into Cardiovascular Disease Collaboration With Merck
- Xenon Enters Into Licensing Agreement With Novartis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Xenon Pharmaceuticals Inc. - Pipeline by Therapy Area and Indication, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline by Stage of Development, H2 2011
- Xenon Pharmaceuticals Inc. - Monotherapy Products in Pipeline, H2 2011
- Xenon Pharmaceuticals Inc. - Phase II, H2 2011
- Xenon Pharmaceuticals Inc. - Phase I, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Therapeutic Class, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Target, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Route of Administration, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Molecule Type, H2 2011
- Xenon Pharmaceuticals Inc. - Recent Pipeline Updates, H2 2011
- Xenon Pharmaceuticals Inc. - Dormant Developmental Projects, 2010
- Xenon Pharmaceuticals Inc., Deals Summary
- Xenon Pharmaceuticals Secures $31 Million In Financing
- Isis Pharmaceuticals Enters Into Collaboration With Xenon Pharmaceuticals
- Xenon Pharmaceuticals Enters Into Collaboration Agreement With DDI
- Xenon Enters Into Research Agreement With Roche
- Takeda Pharmaceutical Enters Into An Agreement With Xenon
- Xenon Pharmaceuticals Enters Into Cardiovascular Disease Collaboration With Merck
- Xenon Enters Into Licensing Agreement With Novartis
- List of Figures
- Xenon Pharmaceuticals Inc. - Pipeline by Therapy Area and Indication, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline by Stage of Development, H2 2011
- Xenon Pharmaceuticals Inc. - Monotherapy Products in Pipeline, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Therapeutic Class, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Target, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Route of Administration, H2 2011
- Xenon Pharmaceuticals Inc. - Pipeline By Molecule Type, H2 2011
Share this report
Other tasks Related Markets Pharmaceuticals Company Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
